ICD-10-CM · Multi-region

M02.89

M02.89 identifies reactive arthropathy affecting multiple joint sites simultaneously, triggered by an infection elsewhere in the body rather than direct joint invasion by a pathogen.

Verified May 8, 2026 · 5 sources ↓

Status
Billable
Chapter
13
Related CPT
10
Region
Multi-region
Drawn from CDCICD10DataAAPCCMS

Documentation tips

What should appear in the chart to support M02.89.

Source · Editorial brief grounded in 5 cited references ↓

  • Name every affected joint explicitly in the assessment — the multiple-sites designation requires documentation of two or more distinct anatomical locations.
  • Identify and code the underlying triggering infection first (e.g., A04.6 for Yersinia enterocolitica, B15–B19 for viral hepatitis); M02.89 is a manifestation code and must not be sequenced as the principal diagnosis.
  • Record how the diagnosis of reactive arthritis was established — recent infection history, positive serology (HLA-B27, ESR, CRP, stool culture), and imaging or arthrocentesis findings that rule out septic arthritis.
  • Document the absence of organisms in the joint fluid if arthrocentesis was performed — this supports the reactive (indirect infection) classification over a direct infectious arthropathy.
  • Note the timeline: reactive arthritis typically follows the triggering infection by days to weeks; documenting onset relative to the infection strengthens the reactive etiology in the medical record.

Related CPT procedures

Procedure codes commonly billed with M02.89. Linking the right diagnosis to the right procedure is what establishes medical necessity.

Source · CMS LCDs · AAOS specialty guidance · claims-pattern analysis

Common coding pitfalls

The recurring mistakes coders make with M02.89 and adjacent codes.

Source · Editorial brief grounded in CDC ICD-10-CM tabular guidance, AAOS coding references, and cited references ↓

  • Sequencing M02.89 as the principal diagnosis — it is a manifestation code and must follow the code for the underlying disease (e.g., A04.6, I33.0, B15–B19).
  • Using M02.89 when only one joint is affected — if laterality and site are clearly documented for a single joint, use the appropriate site-specific M02.8x1/M02.8x2 code instead.
  • Confusing M02.89 with Reiter's disease — reactive arthritis presenting as the classic triad (arthritis, urethritis, conjunctivitis) belongs under M02.3x, not M02.8x.
  • Defaulting to M02.89 when M02.80 (unspecified site) is more accurate — multiple sites requires affirmative documentation of polyarticular involvement, not just an unspecified location.
  • Omitting the underlying infection code entirely, which leaves an incomplete claim and may trigger a medical necessity denial from payers expecting a complete etiology-manifestation pair.

Clinical context

Source · Editorial summary grounded in 5 cited references ↓

Use M02.89 when a patient presents with inflammatory joint involvement at two or more anatomically distinct sites — for example, simultaneous knee and ankle synovitis — and the arthritis is reactive (i.e., the immune response to a remote infection drives the joint disease, not direct microbial invasion of the joint). Qualifying triggers include enteritis due to Yersinia enterocolitica (A04.6), viral hepatitis (B15–B19), infective endocarditis (I33.0), and congenital syphilis with Clutton's joints (A50.5). M02.89 is a manifestation code: the tabular instruction requires you to code first the underlying disease, making M02.89 a secondary code in the claim sequence.

If the reactive arthritis is limited to a single, clearly identified joint, use the site-specific sibling codes under M02.8 (e.g., M02.861 for right knee, M02.871 for right ankle and foot). Drop to M02.80 only when the site is genuinely undocumented. M02.89 is the correct choice when the record explicitly documents polyarticular involvement or when the clinician's assessment names multiple affected joints. Reiter's disease (reactive arthritis triad) has its own category under M02.3x and should not be reported with M02.89.

This code also appears on CMS coverage determination lists for amniotic and placental-derived product policies, meaning it may support or limit coverage eligibility depending on the LCD. Confirm payer-specific LCD/NCD requirements before submitting claims that include biologic or regenerative medicine procedures.

Sibling codes

Other billable codes under M02.8 (laterality / anatomic variants).

Frequently asked questions

Source · Generated from the editorial pipeline, verified against 5 cited references ↓

01Does M02.89 require a 'code first' instruction?
Yes. M02.89 is a manifestation code. Per the tabular, you must code first the underlying disease — for example, A04.6 for Yersinia enterocolitica enteritis or a B15–B19 code for viral hepatitis. M02.89 always appears as a secondary code on the claim.
02What is the difference between M02.89 and M02.80?
M02.80 is for reactive arthropathy at an unspecified site — use it when the record doesn't document which joint is involved. M02.89 is for documented polyarticular involvement at multiple distinct sites. If the note names two or more joints, M02.89 is correct.
03Can I use M02.89 for Reiter's disease with multiple joint involvement?
No. Reiter's disease (reactive arthritis with the classic triad) is classified under M02.3x, not M02.89. The M02.8x subcategory covers 'other' reactive arthropathies that do not meet the Reiter's criteria.
04Which CPT codes are commonly paired with M02.89 in an orthopedic setting?
Joint aspiration or injection (20610, 20611) for diagnostic or therapeutic arthrocentesis of a large joint, and imaging codes such as 73560 or 73564 for knee X-rays, are frequent companions. Office E/M codes (99213–99215) apply for the evaluation encounter.
05Does M02.89 appear on any CMS coverage determination lists that could affect reimbursement?
Yes. CMS LCD articles covering amniotic and placental-derived products list M02.89 as a qualifying diagnosis. Verify the applicable LCD for your jurisdiction before billing regenerative medicine procedures, as coverage and non-coverage determinations vary by contractor.
06Is M02.89 valid for FY2026 (dates of service on or after October 1, 2025)?
Yes. M02.89 is an active, billable code in the FY2026 ICD-10-CM code set, effective October 1, 2025, per the CDC ICD-10-CM Tabular List 2026.
07What documentation differentiates reactive arthropathy (M02.89) from septic arthritis?
Reactive arthropathy involves no organisms or antigens in the joint itself — the infection is remote. Documenting negative joint fluid cultures and a temporally linked antecedent infection (e.g., recent gastroenteritis) supports M02.89 and distinguishes it from septic arthritis codes under M00.

Mira AI Scribe

Mira's AI scribe captures the key elements for M02.89: names and laterality of all affected joints, the antecedent infection with dates of onset, relevant lab findings (HLA-B27, ESR, CRP, cultures), and arthrocentesis results confirming no direct organism involvement. Capturing this at the point of care prevents manifestation sequencing errors and supports the polyarticular specificity required to justify M02.89 over M02.80.

See how Mira captures M02.89 documentation

Related ICD-10 codes

Ready?

Ready to transform your orthopedic practice?

See how orthopedic practices are running documentation, billing, and operations on a single voice-first platform.

Get started for free